Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ASND with free AI briefings, catalyst countdowns, and dilution alerts.

ASND · Ascendis Pharma A/S

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$964.4M Cash on Hand
CF+ Cash Runway
Follow ASND by email Get an email when ASND reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ASND, unsubscribe in one click. Privacy

📣 What ASND Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Lonapegsomatropin
FDA approved Aug 2021 · Skytrofa
Achondroplasia Phase 3 · NCT07924059 Not yet recruiting
Navepegritide
FDA approved Feb 2026 · Yuviwel
Hypochondroplasia Phase 3 · NCT07917143 Not yet recruiting
Palopegteriparatide
FDA approved Aug 2024 · Yorvipath
Hypoparathyroidism N/A · NCT05654701 Approved for marketing
TransCon hGH Growth Hormone Deficiency, Pediatric Phase 3 · NCT03344458 Completed
TransCon CNP Achondroplasia Phase 2/3 · NCT05929807 Enrolling by invitation
Once daily subcutaneous injection of Genotropin Growth Hormone Deficiency, Pediatric Phase 3 · NCT02781727 Completed
Once weekly subcutaneous injection of TransCon… Growth Hormone Deficiency, Pediatric Phase 3 · NCT02781727 Completed
Trastuzumab Emtansine Advanced Solid Tumor Phase 1/2 · NCT05081609 Active not recruiting
ACP-001 Growth Hormone Deficiency (GHD) Phase 2 · NCT01947907 Completed
Resiquimod Hydrogel-based Sustained-release… Advanced Solid Tumor Phase 1/2 · NCT05081609 Active not recruiting
Combination of Navepegritide and… Achondroplasia Phase 2 · NCT06433557 Active not recruiting
Chemotherapy drug Advanced Solid Tumor Phase 1/2 · NCT05081609 Active not recruiting
TransCon Treprostinil Healthy Volunteers Phase 1 · NCT03803163 Terminated

Also used in these trials (approved or third-party drugs, not ASND's own candidates): Somatropin, Trastuzumab, TransCon IL-2 β/γ, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ASND holds $964.4M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASND files for a raise →

👥 Who Owns ASND

Insiders 0.8% Institutions (487 holders) 99.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 8,194,812 13.22% 2026-09-30
Westfield Capital Management Company, L. Institution (13G, 5%+) 5,185,696 8.37% 2025-12-31
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 3,719,452 6.00% 2026-03-31
FMR LLC Institution (13G, 5%+) 3,425,993 5.53% 2026-09-30
Jan Moller Mikkelsen
Director
Insider 453,403 0.73% 2026-03-18
Kennett Sprogoe
EVP & Head of Research & Product Develop
Insider 19,570 0.03% 2026-03-18
Pedersen Anni Lotte Kirstine Sonderbjerg
EVP & Chief Admin Officer
Insider 19,460 0.03% 2026-03-18
Scott Thomas Smith
EVP & Chief Financial Officer
Insider 4,367 0.01% 2026-06-02
Lars Holtug
Director
Insider 4,000 0.01% 2026-09-02
Albert Cha
Director
Insider 3,730 0.01% 2026-03-18
Jean Jacques Bienaime
Director · +9,160 options
Insider 2,900 0.00% 2026-08-14
Siham Imani
Director
Insider 2,317 0.00% 2026-03-18

Share count 61,977,408 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ASND picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASND and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.